Antiplatelet therapy: new pharmacological agents and changing paradigms

Summary Recurrent atherothrombotic events in patients with acute coronary syndromes (ACS) and/or those undergoing percutaneous coronary intervention (PCI) are essentially platelet‐driven processes, underscoring the need for effective pharmacological platelet inhibition. Dual antiplatelet therapy wit...

Full description

Saved in:
Bibliographic Details
Published in:Journal of thrombosis and haemostasis 2013-06, Vol.11, p.316-329
Main Authors: Capodanno, D., Ferreiro, J. L., Angiolillo, D. J.
Format: Article
Language:English
Subjects:
Acute coronary syndromes
Angina pectoris
cangrelor
clopidogrel
Heart attacks
Humans
Platelet Aggregation Inhibitors - pharmacology
prasugrel
thrombosis
ticagrelor
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Recurrent atherothrombotic events in patients with acute coronary syndromes (ACS) and/or those undergoing percutaneous coronary intervention (PCI) are essentially platelet‐driven processes, underscoring the need for effective pharmacological platelet inhibition. Dual antiplatelet therapy with aspirin and clopidogrel has been, for over a decade, the mainstay of antiplatelet management in ACS/PCI. However, atherothrombotic events continue to occur in a relevant proportion of subjects despite the benefit of this combination, which has led to the clinical development of newer and more potent antiplatelet drugs. Two of these, prasugrel and ticagrelor, have been recently approved for clinical use. The scope of this manuscript is to provide an up‐to‐date overview on new antiplatelet drugs in the setting of ACS and PCI, including the most recent advances on newly approved agents as well as on emerging compounds in clinical development.
ISSN:1538-7933
1538-7836
1538-7836
DOI:10.1111/jth.12219